血管紧张素转换酶抑制剂 (ACEI)已经成为治疗心力衰竭的基本用药 ,血管紧张素II受体阻滞剂(ARB)也已经应用于心力衰竭的治疗。两者作用机制的异同点促使人们思考联合应用ACEI与ARB的临床价值及可行性 ,近年来一些大型的临床试验试图给出明确的答案 ,却给人们提出了更多的问题 Angiotensin-converting enzyme inhibitors (ACEIs) have become essential for the treatment of heart failure and angiotensin II receptor blockers (ARBs) have also been used in the treatment of heart failure. The similarities and differences between the two mechanisms of action prompted people to think about the clinical value and feasibility of the combination of ACEI and ARB. In recent years, some large-scale clinical trials have attempted to give a clear answer but have given rise to more questions